Negative affective states and cognitive impairments in nicotine dependence

Neuroscience and Biobehavioral Reviews

Volumn 58, Issue , 2015, Pages 168-185

  Hall, F Scott ^a   Der Avakian, Andre ^b   Gould, Thomas J ^c   Markou, Athina ^b   Shoaib, Mohammed ^d   Young, Jared W ^b,e  

^a UNIVERSITY OF TOLEDO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TEMPLE UNIVERSITY   (United States)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Cognitive impairment; Negative affect; Negative reinforcement; Nicotine

Indexed keywords

AMFEBUTAMONE; ATOMOXETINE; BACLOFEN; BUSPIRONE; CARVEDILOL; CLONIDINE; CYCLOSERINE; CYTOSINE; LABETALOL; LOBELINE; MECAMYLAMINE; NALTREXONE; NICOTINE; NORTRIPTYLINE; REBOXETINE; RIMONABANT; SELEGILINE; SURINABANT; TIAGABINE; TOPIRAMATE; VARENICLINE; VIGABATRIN;

AFFECT; ANALGESIA; ANXIETY; ATTENTION; COGNITIVE DEFECT; EXPERIMENTAL ANIMAL; HUMAN; MENTAL HEALTH; MORBIDITY; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; REINFORCEMENT; REVIEW; REWARD; SELF MEDICATION; SMOKING CESSATION; TOBACCO DEPENDENCE; COGNITION DISORDERS; COMPLICATION; MOOD DISORDERS; PSYCHOLOGY;

COGNITION DISORDERS; HUMANS; MOOD DISORDERS; TOBACCO USE DISORDER;

EID: 84949320994     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2015.06.004     Document Type: Review

References (273)

1. Abdolahi A., Acosta G., Breslin F.J., Hemby S.E., Lynch W.J. Incubation of nicotine seeking is associated with enhanced protein kinase A-regulated signaling of dopamine- and cAMP-regulated phosphoprotein of 32kDa in the insular cortex. Eur. J. Neurosci. 2010, 31:733-741.
2. Abreu-Villaca Y., Queiroz-Gomes Fdo E., Dal Monte A.P., Filgueiras C.C., Manhaes A.C. Individual differences in novelty-seeking behavior but not in anxiety response to a new environment can predict nicotine consumption in adolescent C57BL/6 mice. Behav. Brain Res. 2006, 167:175-182.
3. Adler L.E., Hoffer L.D., Wiser A., Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am. J. Psychiatry 1993, 150:1856-1861.
4. Adriani W., Granstrem O., Macri S., Izykenova G., Dambinova S., Laviola G. Behavioral and neurochemical vulnerability during adolescence in mice: studies with nicotine. Neuropsychopharmacology 2004, 29:869-878.
5. Allison C., Shoaib M. Nicotine improves performance in an attentional set shifting task in rats. Neuropharmacology 2013, 64:314-320.
6. Andre J.M., Gulick D., Portugal G.S., Gould T.J. Nicotine withdrawal disrupts both foreground and background contextual fear conditioning but not pre-pulse inhibition of the acoustic startle response in C57BL/6 mice. Behav. Brain Res. 2008, 190:174-181.
7. Andre J.M., Leach P.T., Gould T.J. Nicotine ameliorates NMDA receptor antagonist-induced deficits in contextual fear conditioning through high-affinity nicotinic acetylcholine receptors in the hippocampus. Neuropharmacology 2011, 60:617-625.
8. Andreasen J.T., Henningsen K., Bate S., Christiansen S., Wiborg O. Nicotine reverses anhedonic-like response and cognitive impairment in the rat chronic mild stress model of depression: comparison with sertraline. J. Psychopharmacol. 2011, 25:1134-1141.
9. Arime Y., Kasahara Y., Hall F.S., Uhl G.R., Sora I. Cortico-subcortical neuromodulation involved in the amelioration of prepulse inhibition deficits in dopamine transporter knockout mice. Neuropsychopharmacology 2012, 37:2522-2530.
10. Atzori G., Lemmonds C.A., Kotler M.L., Durcan M.J., Boyle J. Efficacy of a nicotine (4mg)-containing lozenge on the cognitive impairment of nicotine withdrawal. J. Clin. Psychopharmacol. 2008, 28:667-674.
11. Azizbeigi R., Ahmadi S., Babapour V., Rezayof A., Zarrindast M.R. Nicotine restores morphine-induced memory deficit through the D1 and D2 dopamine receptor mechanisms in the nucleus accumbens. J. Psychopharmacol. 2011, 25:1126-1133.
12. Bailey C.D., De Biasi M., Fletcher P.J., Lambe E.K. The nicotinic acetylcholine receptor alpha5 subunit plays a key role in attention circuitry and accuracy. J. Neurosci. 2010, 30:9241-9252.
13. Balerio G.N., Aso E., Maldonado R. Involvement of the opioid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology (Berl) 2005, 181:260-269.
14. Balerio G.N., Aso E., Maldonado R. Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology (Berl) 2006, 184:504-513.
15. Batel P. Addiction and schizophrenia. Eur. Psychiatry 2000, 15:115-122.
16. Beckham J.C., Dennis M.F., McClernon F.J., Mozley S.L., Collie C.F., Vrana S.R. The effects of cigarette smoking on script-driven imagery in smokers with and without posttraumatic stress disorder. Addict. Behav. 2007, 32:2900-2915.
17. Beckham J.C., Roodman A.A., Shipley R.H., Hertzberg M.A., Cunha G.H., Kudler H.S., Levin E.D., Rose J.E., Fairbank J.A. Smoking in Vietnam combat veterans with posttraumatic-stress-disorder. J. Trauma Stress 1995, 8:461-472.
18. Bedi G., Preston K.L., Epstein D.H., Heishman S.J., Marrone G.F., Shaham Y., de Wit H. Incubation of cue-induced cigarette craving during abstinence in human smokers. Biol. Psychiatry 2011, 69:708-711.
19. Beer A., Slotkin T.A., Seidler F.J., Aldridge J.E., Yanai J. Nicotine therapy in adulthood reverses the synaptic and behavioral deficits elicited by prenatal exposure to phenobarbital. Neuropsychopharmacology 2005, 30:156-165.
20. Belin D., Mar A.C., Dalley J.W., Robbins T.W., Everitt B.J. High impulsivity predicts the switch to compulsive cocaine-taking. Science 2008, 320:1352-1355.
21. Bernal M.C., Vicens P., Carrasco M.C., Redolat R. Effects of nicotine on spatial learning in C57BL mice. Behav. Pharmacol. 1999, 10:333-336.
22. Berrendero F., Kieffer B.L., Maldonado R. Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. J. Neurosci. 2002, 22:10935-10940.
23. Berrendero F., Mendizabal V., Robledo P., Galeote L., Bilkei-Gorzo A., Zimmer A., Maldonado R. Nicotine-induced antinociception, rewarding effects, and physical dependence are decreased in mice lacking the preproenkephalin gene. J. Neurosci. 2005, 25:1103-1112.
24. Biala G., Kruk M. Cannabinoid receptor ligands suppress memory-related effects of nicotine in the elevated plus maze test in mice. Behav. Brain Res. 2008, 192:198-202.
25. Biala G., Weglinska B. Blockade of the expression of mecamylamine-precipitated nicotine withdrawal by calcium channel antagonists. Pharmacol. Res. 2005, 51:483-488.
26. Bilkei-Gorzo A., Racz I., Michel K., Darvas M., Maldonado R., Zimmer A. A common genetic predisposition to stress sensitivity and stress-induced nicotine craving. Biol. Psychiatry 2008, 63:164-171.
27. Blokhina E.A., Kashkin V.A., Zvartau E.E., Danysz W., Bespalov A.Y. Effects of nicotinic and NMDA receptor channel blockers on intravenous cocaine and nicotine self-administration in mice. Eur. Neuropsychopharmacol. 2005, 15:219-225.
28. Boess F.G., De Vry J., Erb C., Flessner T., Hendrix M., Luithle J., Methfessel C., Riedl B., Schnizler K., van der Staay F.J., van Kampen M., Wiese W.B., Koenig G. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents. J. Pharmacol. Exp. Ther. 2007, 321:716-725.
29. Bontempi B., Whelan K.T., Risbrough V.B., Lloyd G.K., Menzaghi F. Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors. Neuropsychopharmacology 2003, 28:1235-1246.
30. Booker T.K., Butt C.M., Wehner J.M., Heinemann S.F., Collins A.C. Decreased anxiety-like behavior in beta3 nicotinic receptor subunit knockout mice. Pharmacol. Biochem. Behav. 2007, 87:146-157.
31. Bovet-Nitti F. Facilitation of simultaneous visual discrimination by nicotine in four "inbred" strains of mice. Psychopharmacologia 1969, 14:193-199.
32. Bovet D., Bovet-Nitti F., Oliverio A. Effects of nicotine on avoidance conditioning of inbred strains of mice. Psychopharmacologia 1966, 10:1-5.
33. Braff D.L., Geyer M.A., Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 2001, 156:234-258.
34. Breslau N., Kilbey M., Andreski P. Nicotine dependence, major depression, and anxiety in young adults. Arch. Gen. Psychiatry 1991, 48:1069-1074.
35. Brioni J.D., Arneric S.P. Nicotinic receptor agonists facilitate retention of avoidance training: participation of dopaminergic mechanisms. Behav. Neural Biol. 1993, 59:57-62.
36. Buckley T.C., Holohan D.R., Mozley S.L., Walsh K., Kassel J. The effect of nicotine and attention allocation on physiological and self-report measures of induced anxiety in PTSD: a double-blind placebo-controlled trial. Exp. Clin. Psychopharmacol. 2007, 15:154-164.
37. Caille S., Clemens K., Stinus L., Cador M. Modeling nicotine addiction in rats. Methods Mol. Biol. 2012, 829:243-256.
38. Caldarone B.J., King S.L., Picciotto M.R. Sex differences in anxiety-like behavior and locomotor activity following chronic nicotine exposure in mice. Neurosci. Lett. 2008, 439:187-191.
39. Carli M., Robbins T.W., Evenden J.L., Everitt B.J. Effects of lesions to ascending noradrenergic neurones on performance of a 5-choice serial reaction task in rats; implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal. Behav. Brain Res. 1983, 9:361-380.
40. Carlson J.M., Gilbert D.G., Riise H., Rabinovich N.E., Sugai C., Froeliger B. Serotonin transporter genotype and depressive symptoms moderate effects of nicotine on spatial working memory. Exp. Clin. Psychopharmacol. 2009, 17:173-180.
41. Castane A., Valjent E., Ledent C., Parmentier M., Maldonado R., Valverde O. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 2002, 43:857-867.
42. Castellano C. Effects of nicotine on discrimination learning, consolidation and learned behaviour in two inbred strains of mice. Psychopharmacology (Berl) 1976, 48:37-43.
43. Chen L.S., Xian H., Grucza R.A., Saccone N.L., Wang J.C., Johnson E.O., Breslau N., Hatsukami D., Bierut L.J. Nicotine dependence and comorbid psychiatric disorders: examination of specific genetic variants in the CHRNA5-A3-B4 nicotinic receptor genes. Drug Alcohol Depend. 2012, 123:S42-S51.
44. Ciamei A., Aversano M., Cestari V., Castellano C. Effects of MK-801 and nicotine combinations on memory consolidation in CD1 mice. Psychopharmacology (Berl) 2001, 154:126-130.
45. Cisler J.M., Amstadter A.B., Begle A.M., Resnick H.S., Danielson C.K., Saunders B.E., Kilpatrick D.G. A prospective examination of the relationships between PTSD, exposure to assaultive violence, and cigarette smoking among a national sample of adolescents. Addict. Behav. 2011, 36:994-1000.
46. Cohen A., Treweek J., Edwards S., Leao R.M., Schulteis G., Koob G.F., George O. Extended access to nicotine leads to a CRF receptor dependent increase in anxiety-like behavior and hyperalgesia in rats. Addict. Biol. 2015, 20:56-68.
47. Colamussi L., Bovbjerg D.H., Erblich J. Stress- and cue-induced cigarette craving: effects of a family history of smoking. Drug Alcohol Depend. 2007, 88:251-258.
48. Contet C., Whisler K.N., Jarrell H., Kenny P.J., Markou A. Patterns of responding differentiate intravenous nicotine self-administration from responding for a visual stimulus in C57BL/6J mice. Psychopharmacology (Berl) 2010, 212:283-299.
49. Cook J., Spring B., McChargue D., Doran N. Effects of anhedonia on days to relapse among smokers with a history of depression: a brief report. Nicotine Tob. Res. 2010, 12:978-982.
50. Covey L.S., Glassman A.H., Stetner F. Major depression following smoking cessation. Am. J. Psychiatry 1997, 154:263-265.
51. Covey L.S., Glassman A.H., Stetner F., Becker J. Effect of history of alcoholism or major depression on smoking cessation. Am. J. Psychiatry 1993, 150:1546-1547.
52. Cryan J.F., Bruijnzeel A.W., Skjei K.L., Markou A. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) 2003, 168:347-358.
53. D'Souza M.S., Markou A. Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits. Neuropharmacology 2012, 62:1564-1573.
54. Dalley J.W., Fryer T.D., Brichard L., Robinson E.S., Theobald D.E., Laane K., Pena Y., Murphy E.R., Shah Y., Probst K., Abakumova I., Aigbirhio F.I., Richards H.K., Hong Y., Baron J.C., Everitt B.J., Robbins T.W. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 2007, 315:1267-1270.
55. Damaj M.I., Kao W., Martin B.R. Characterization of spontaneous and precipitated nicotine withdrawal in the mouse. J. Pharmacol. Exp. Ther. 2003, 307:526-534.
56. Davis J.A., Gould T.J. The effects of DHBE and MLA on nicotine-induced enhancement of contextual fear conditioning in C57BL/6 mice. Psychopharmacology (Berl) 2006, 184:345-352.
57. Davis J.A., Gould T.J. Atomoxetine reverses nicotine withdrawal-associated deficits in contextual fear conditioning. Neuropsychopharmacology 2007, 32:2011-2019.
58. Davis J.A., Gould T.J. Beta 2 subunit-containing nicotinic receptors mediate the enhancing effect of nicotine on trace cued fear conditioning in C57BL/6 mice. Psychopharmacology (Berl) 2007, 190:343-352.
59. Davis J.A., Gould T.J. Hippocampal nAChRs mediate nicotine withdrawal-related learning deficits. Eur. Neuropsychopharmacol. 2009, 19:551-561.
60. Davis J.A., James J.R., Siegel S.J., Gould T.J. Withdrawal from chronic nicotine administration impairs contextual fear conditioning in C57BL/6 mice. J. Neurosci. 2005, 25:8708-8713.
61. Davis J.A., Kenney J.W., Gould T.J. Hippocampal alpha4beta2 nicotinic acetylcholine receptor involvement in the enhancing effect of acute nicotine on contextual fear conditioning. J. Neurosci. 2007, 27:10870-10877.
62. Davis J.A., Porter J., Gould T.J. Nicotine enhances both foreground and background contextual fear conditioning. Neurosci. Lett. 2006, 394:202-205.
63. de Bruin N.M., Fransen F., Duytschaever H., Grantham C., Megens A.A. Attentional performance of (C57BL/6Jx129Sv)F2 mice in the five-choice serial reaction time task. Physiol. Behav. 2006, 89:692-703.
64. de Leon J., Dadvand M., Canuso C., White A.O., Stanilla J.K., Simpson G.M. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am. J. Psychiatry 1995, 152:453-455.
65. Decker M.W., Brioni J.D., Sullivan J.P., Buckley M.J., Radek R.J., Raszkiewicz J.L., Kang C.H., Kim D.J., Giardina W.J., Wasicak J.T., et al. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J. Pharmacol. Exp. Ther. 1994, 270:319-328.
66. Der-Avakian A., D'Souza M.S., Pizzagalli D.A., Markou A. Assessment of reward responsiveness in the response bias probabilistic reward task in rats: implications for cross-species translational research. Transl. Psychiatry 2013, 3(August):e297.
67. Der-Avakian A., Markou A. Withdrawal from chronic exposure to amphetamine, but not nicotine, leads to an immediate and enduring deficit in motivated behavior without affecting social interaction in rats. Behav. Pharmacol. 2010, 21:359-368.
68. Dickerson D.L., O'Malley S.S., Canive J., Thuras P., Westermeyer J. Nicotine dependence and psychiatric and substance use comorbidities in a sample of American Indian male veterans. Drug Alcohol Depend. 2009, 99:169-175.
69. Dolan S.L., Sacco K.A., Termine A., Seyal A.A., Dudas M.M., Vessicchio J.C., Wexler B.E., George T.P. Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophrenia. Schizophr. Res. 2004, 70:261-275.
70. Doran N., Spring B., McChargue D. Effect of impulsivity on craving and behavioral reactivity to smoking cues. Psychopharmacology (Berl) 2007, 194:279-288.
71. Elrashidi M.Y., Ebbert J.O. Emerging drugs for the treatment of tobacco dependence: 2014 update. Expert Opin. Emerg. Drugs 2014, 19:243-260.
72. Epping-Jordan M.P., Watkins S.S., Koob G.F., Markou A. Dramatic decreases in brain reward function during nicotine withdrawal. Nature 1998, 393:76-79.
73. Feldner M.T., Babson K.A., Zvolensky M.J. Smoking, traumatic event exposure, and post-traumatic stress: a critical review of the empirical literature. Clin. Psychol. Rev. 2007, 27:14-45.
74. Feuerbach D., Lingenhoehl K., Olpe H.R., Vassout A., Gentsch C., Chaperon F., Nozulak J., Enz A., Bilbe G., McAllister K., Hoyer D. The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology 2009, 56:254-263.
75. Field M., Rush M., Cole J., Goudie A. The smoking Stroop and delay discounting in smokers: effects of environmental smoking cues. J. Psychopharmacol. 2007, 21:603-610.
76. Fowler C.D., Kenny P.J. Intravenous nicotine self-administration and cue-induced reinstatement in mice: effects of nicotine dose, rate of drug infusion and prior instrumental training. Neuropharmacology 2011, 61:687-698.
77. Fowler C.D., Lu Q., Johnson P.M., Marks M.J., Kenny P.J. Habenular alpha5 nicotinic receptor subunit signalling controls nicotine intake. Nature 2011, 471:597-601.
78. Froeliger B., Gilbert D.G., McClernon F.J. Effects of nicotine on novelty detection and memory recognition performance: double-blind, placebo-controlled studies of smokers and nonsmokers. Psychopharmacology (Berl) 2009, 205:625-633.
79. Fuemmeler B.F., Kollins S.H., McClernon F.J. Attention deficit hyperactivity disorder symptoms predict nicotine dependence and progression to regular smoking from adolescence to young adulthood. J. Pediatr. Psychol. 2007, 32:1203-1213.
80. Galeote L., Berrendero F., Bura S.A., Zimmer A., Maldonado R. Prodynorphin gene disruption increases the sensitivity to nicotine self-administration in mice. Int. J. Neuropsychopharmacol. 2009, 12:615-625.
81. Gatto G.J., Bohme G.A., Caldwell W.S., Letchworth S.R., Traina V.M., Obinu M.C., Laville M., Reibaud M., Pradier L., Dunbar G., Bencherif M. TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. CNS Drug Rev. 2004, 10:147-166.
82. Gawin F.H., Kleber H.D. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations. Arch. Gen. Psychiatry 1986, 43:107-113.
83. George O., Ghozland S., Azar M.R., Cottone P., Zorrilla E.P., Parsons L.H., O'Dell L.E., Richardson H.N., Koob G.F. CRF-CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:17198-17203.
84. George O., Lloyd A., Carroll F.I., Damaj M.I., Koob G.F. Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration. Psychopharmacology (Berl) 2011, 213:715-722.
85. George T.P., Termine A., Sacco K.A., Allen T.M., Reutenauer E., Vessicchio J.C., Duncan E.J. A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: involvement of nicotinic receptor mechanisms. Schizophr. Res. 2006, 87:307-315.
86. George T.P., Vessicchio J.C., Termine A., Sahady D.M., Head C.A., Pepper W.T., Kosten T.R., Wexler B.E. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 2002, 26:75-85.
87. Glassman A.H. Cigarette-smoking - implications for psychiatric-illness. Am. J. Psychiatry 1993, 150:546-553.
88. Glassman A.H. Psychiatry and cigarettes. Arch. Gen. Psychiatry 1998, 55:692-693.
89. Glassman A.H., Covey L.S., Dalack G.W., Stetner F., Rivelli S.K., Fleiss J., Cooper T.B. Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin. Pharmacol. Ther. 1993, 54:670-679.
90. Glassman A.H., Stetner F., Walsh B.T., Raizman P.S., Fleiss J.L., Cooper T.B., Covey L.S. Heavy smokers, smoking cessation, and clonidine. Results of a double-blind, randomized trial. JAMA 1988, 259:2863-2866.
91. Glautier S. Measures and models of nicotine dependence: positive reinforcement. Addiction 2004, 99(Suppl. 1):30-50.
92. Goldstein M.G. Bupropion sustained release and smoking cessation. J. Clin. Psychiatry 1998, 59(Suppl. 4):66-72.
93. Gonzales D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B., Watsky E.J., Gong J., Williams K.E., Reeves K.R. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296:47-55.
94. Gould T.J. Nicotine produces a within-subject enhancement of contextual fear conditioning in C57BL/6 mice independent of sex. Integr. Physiol. Behav. Sci. 2003, 38:124-132.
95. Gould T.J., Feiro O., Moore D. Nicotine enhances trace cued fear conditioning but not delay cued fear conditioning in C57BL/6 mice. Behav. Brain Res. 2004, 155:167-173.
96. Gould T.J., Higgins J.S. Nicotine enhances contextual fear conditioning in C57BL/6J mice at 1 and 7 days post-training. Neurobiol. Learn. Mem. 2003, 80:147-157.
97. Gould T.J., Lommock J.A. Nicotine enhances contextual fear conditioning and ameliorates ethanol-induced deficits in contextual fear conditioning. Behav. Neurosci. 2003, 117:1276-1282.
98. Gould T.J., Rukstalis M., Lewis M.C. Atomoxetine and nicotine enhance prepulse inhibition of acoustic startle in C57BL/6 mice. Neurosci. Lett. 2005, 377:85-90.
99. Gould T.J., Wehner J.M. Nicotine enhancement of contextual fear conditioning. Behav. Brain Res. 1999, 102:31-39.
100. Grabe H.J., Meyer C., Hapke U., Rumpf H.J., Freyberger H.J., Dilling H., John U. Lifetime-comorbidity of obsessive-compulsive disorder and subclinical obsessive-compulsive disorder in northern Germany. Eur. Arch. Psychiatry Clin. Neurosci. 2001, 251:130-135.
101. Grieder T.E., Sellings L.H., Vargas-Perez H., Ting A.K.R., Siu E.C., Tyndale R.F., van der Kooy D. Dopaminergic signaling mediates the motivational response underlying the opponent process to chronic but not acute nicotine. Neuropsychopharmacology 2010, 35:943-954.
102. Gross T.M., Jarvik M.E., Rosenblatt M.R. Nicotine abstinence produces content-specific Stroop interference. Psychopharmacology (Berl) 1993, 110:333-336.
103. Grottick A.J., Haman M., Wyler R., Higgins G.A. Reversal of a vigilance decrement in the aged rat by subtype-selective nicotinic ligands. Neuropsychopharmacology 2003, 28:880-887.
104. Gulick D., Gould T.J. Interactive effects of ethanol and nicotine on learning in C57BL/6J mice depend on both dose and duration of treatment. Psychopharmacology (Berl) 2008, 196:483-495.
105. Gulick D., Gould T.J. Varenicline ameliorates ethanol-induced deficits in learning in C57BL/6 mice. Neurobiol. Learn. Mem. 2008, 90:230-236.
106. Gulick D., Gould T.J. The hippocampus and cingulate cortex differentially mediate the effects of nicotine on learning versus on ethanol-induced learning deficits through different effects at nicotinic receptors. Neuropsychopharmacology 2009, 34:2167-2179.
107. Gulick D., Gould T.J. Nicotine acts in the anterior cingulate, but not dorsal or ventral hippocampus, to reverse ethanol-induced learning impairments in the plus-maze discriminative avoidance task. Addict. Biol. 2010, 16:176-188.
108. Gulick D., Gould T.J. Nicotine acts in the anterior cingulate, but not dorsal or ventral hippocampus, to reverse ethanol-induced learning impairments in the plus-maze discriminative avoidance task. Addict. Biol. 2011, 16:176-188.
109. Hahn B., Sharples C.G.V., Wonnacott S., Shoaib M., Stolerman P. Attentional effects of nicotinic agonists in rats. Neuropharmacology 2003, 44:1054-1067.
110. Hahn B., Shoaib M., Stolerman I.P. Nicotine-induced enhancement of attention in the five-choice serial reaction time task: the influence of task demands. Psychopharmacology (Berl) 2002, 162:129-137.
111. Hahn B., Shoaib M., Stolerman I.P. Involvement of the prefrontal cortex but not the dorsal hippocampus in the attention-enhancing effects of nicotine in rats. Psychopharmacology (Berl) 2003, 168:271-279.
112. Hahn B., Shoaib M., Stolerman I.P. Selective nicotinic receptor antagonists: effects on attention and nicotine-induced attentional enhancement. Psychopharmacology (Berl) 2011, 217:75-82.
113. Hall F.S., Markou A., Levin E.D., Uhl G.R. Mouse models for studying genetic influences on factors determining smoking cessation success in humans. Ann. N. Y. Acad. Sci. 2012, 1248:39-70.
114. Hall S.M., Reus V.I., Munoz R.F., Sees K.L., Humfleet G., Hartz D.T., Frederick S., Triffleman E. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch. Gen. Psychiatry 1998, 55:683-690.
115. Harrison A.A., Liem Y.T.B., Markou A. Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. Neuropsychopharmacology 2001, 25:55-71.
116. Hartsough C.S., Lambert N.M. Pattern and progression of drug use among hyperactives and controls: a prospective short-term longitudinal study. J. Child Psychol. Psychiatry 1987, 28:543-553.
117. Hatsukami D., Fletcher L., Morgan S., Keenan R., Amble P. The effects of varying cigarette deprivation duration on cognitive and performance tasks. J. Subst. Abuse 1989, 1:407-416.
118. Hayase T. Depression-related anhedonic behaviors caused by immobilization stress: a comparison with nicotine-induced depression-like behavioral alterations and effects of nicotine and/or "antidepressant" drugs. J. Toxicol. Sci. 2011, 36:31-41.
119. Heishman S.J., Kleykamp B.A., Singleton E.G. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology (Berl) 2010, 210:453-469.
120. Heishman S.J., Taylor R.C., Henningfield J.E. Nicotine and smoking: a review of effects on nicotine performance. Exp. Clin. Psychopharmacol. 1994, 2:345-395.
121. Heron-Delaney M., Kenardy J., Charlton E., Matsuoka Y. A systematic review of predictors of posttraumatic stress disorder (PTSD) for adult road traffic crash survivors. Injury 2013, 44:1413-1422.
122. Hoyle E., Genn R.F., Fernandes C., Stolerman I.P. Impaired performance of alpha7 nicotinic receptor knockout mice in the five-choice serial reaction time task. Psychopharmacology (Berl) 2006, 189:211-223.
123. Hughes J.R., Gust S.W., Skoog K., Keenan R.M., Fenwick J.W. Symptoms of tobacco withdrawal - a replication and extension. Arch. Gen. Psychiatry 1991, 48:52-59.
124. Hughes J.R., Keenan R.M., Yellin A. Effect of tobacco withdrawal on sustained attention. Addict. Behav. 1989, 14:577-580.
125. Humby T., Laird F.M., Davies W., Wilkinson L.S. Visuospatial attentional functioning in mice: interactions between cholinergic manipulations and genotype. Eur. J. Neurosci. 1999, 11:2813-2823.
126. Hunter R.G., Bloss E.B., McCarthy K.J., McEwen B.S. Regulation of the nicotinic receptor alpha7 subunit by chronic stress and corticosteroids. Brain Res. 2010, 1325:141-146.
127. Hurt R.D., Sachs D.P.L., Glover E.D., Offord K.P., Johnston J.A., Dale L.C., Khayrallah M.A., Schroeder D.R., Glover P.N., Sullivan C.R., Croghan I.T., Sullivan P.M. A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med. 1997, 337:1195-1202.
128. Jackson K.J., Carroll F.I., Negus S.S., Damaj M.I. Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse. Psychopharmacology (Berl) 2010, 210:285-294.
129. Jackson K.J., Fanous A.H., Chen J.C., Kendler K.S., Chen X.N. Variants in the 15q25 gene cluster are associated with risk for schizophrenia and bipolar disorder. Psychiatry Genet. 2013, 23:20-28.
130. Jackson K.J., Kota D.H., Martin B.R., Damaj M.I. The role of various nicotinic receptor subunits and factors influencing nicotine conditioned place aversion. Neuropharmacology 2009, 56:970-974.
131. Jackson K.J., McIntosh J.M., Brunzell D.H., Sanjakdar S.S., Damaj M.I. The role of alpha6-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal. J. Pharmacol. Exp. Ther. 2009, 331:547-554.
132. Jackson K.J., Walters C.L., Miles M.F., Martin B.R., Damaj M.I. Characterization of pharmacological and behavioral differences to nicotine in C57Bl/6 and DBA/2 mice. Neuropharmacology 2009, 57:347-355.
133. Johnson P.M., Hollander J.A., Kenny P.J. Decreased brain reward function during nicotine withdrawal in C57BL6 mice: evidence from intracranial self-stimulation (ICSS) studies. Pharmacol. Biochem. Behav. 2008, 90:409-415.
134. Jonkman S., Risbrough V.B., Geyer M.A., Markou A. Spontaneous nicotine withdrawal potentiates the effects of stress in rats. Neuropsychopharmacology 2008, 33:2131-2138.
135. Jubelt L.E., Barr R.S., Goff D.C., Logvinenko T., Weiss A.P., Evins A.E. Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia. Psychopharmacology (Berl) 2008, 199:89-98.
136. Kayir H., Uzbay I.T. Nicotine antagonizes caffeine - but not pentylenetetrazole-induced anxiogenic effect in mice. Psychopharmacology (Berl) 2006, 184:464-469.
137. Keenan R.M., Hatsukami D.K., Anton D.J. The effects of short-term smokeless tobacco deprivation on performance. Psychopharmacology (Berl) 1989, 98:126-130.
138. Kenney J.W., Gould T.J. Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine. Mol. Neurobiol. 2008, 38:101-121.
139. Kenney J.W., Gould T.J. Nicotine enhances context learning but not context-shock associative learning. Behav. Neurosci. 2008, 122:1158-1165.
140. Kenney J.W., Raybuck J.D., Gould T.J. Nicotinic receptors in the dorsal and ventral hippocampus differentially modulate contextual fear conditioning. Hippocampus 2012, 22:1681-1690.
141. Kenny P.J., Markou A. Conditioned nicotine withdrawal profoundly decreases the activity of brain reward systems. J. Neurosci. 2005, 25:6208-6212.
142. Keuthen N.J., Niaura R.S., Borrelli B., Goldstein M., DePue J., Murphy C., Gastfriend D., Reiter S.R., Abrams D. Comorbidity, smoking behavior and treatment outcome. Psychother. Psychosom. 2000, 69:244-250.
143. Koenen K.C., Hitsman B., Lyons M.J., Niaura R., McCaffery J., Goldberg J., Eisen S.A., True W., Tsuang M. A twin registry study of the relationship between posttraumatic stress disorder and nicotine dependence in men. Arch. Gen. Psychiatry 2005, 62:1258-1265.
144. Kohl S., Heekeren K., Klosterkotter J., Kuhn J. Prepulse inhibition in psychiatric disorders - apart from schizophrenia. J. Psychiatr. Res. 2013, 47:445-452.
145. Kollins S.H., English J.S., Roley M.E., O'Brien B., Blair J., Lane S.D., McClernon F.J. Effects of smoking abstinence on smoking-reinforced responding, withdrawal, and cognition in adults with and without attention deficit hyperactivity disorder. Psychopharmacology (Berl) 2013, 227:19-30.
146. Kollins S.H., McClernon F.J., Epstein J.N. Effects of smoking abstinence on reaction time variability in smokers with and without ADHD: an ex-Gaussian analysis. Drug Alcohol Depend. 2009, 100:169-172.
147. Koob G.F. Negative reinforcement in drug addiction: the darkness within. Curr. Opin. Neurobiol. 2013, 23:559-563.
148. Koob G.F., Le Moal M. Review. Neurobiological mechanisms for opponent motivational processes in addiction. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2008, 363:3113-3123.
149. Kumari V., Gray J.A. Smoking withdrawal, nicotine dependence and prepulse inhibition of the acoustic startle reflex. Psychopharmacology (Berl) 1999, 141:11-15.
150. Kumari V., Soni W., Sharma T. Influence of cigarette smoking on prepulse inhibition of the acoustic startle response in schizophrenia. Hum. Psychopharmacol. 2001, 16:321-326.
151. Lawrence D., Mitrou F., Zubrick S.R. Smoking and mental illness: results from population surveys in Australia and the United States. BMC Public Health 2009, 9:285.
152. Lee J.L., Milton A.L., Everitt B.J. Cue-induced cocaine seeking and relapse are reduced by disruption of drug memory reconsolidation. J. Neurosci. 2006, 26:5881-5887.
153. LeSage M.G., Burroughs D., Pentel P.R. Effects of nicotine withdrawal on performance under a progressive-ratio schedule of sucrose pellet delivery in rats. Pharmacol. Biochem. Behav. 2006, 83:585-591.
154. Leventhal A.M., Waters A.J., Kahler C.W., Ray L.A., Sussman S. Relations between anhedonia and smoking motivation. Nicotine Tob. Res. 2009, 11:1047-1054.
155. Leventhal A.M., Witt C.F., Zimmerman M. Associations between depression subtypes and substance use disorders. Psychiatry Res. 2008, 161:43-50.
156. Levin E.D., McClernon F.J., Rezvani A.H. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) 2006, 184:523-539.
157. Levin E.D., Petro A., Rezvani A.H., Pollard N., Christopher N.C., Strauss M., Avery J., Nicholson J., Rose J.E. Nicotinic alpha7- or beta2-containing receptor knockout: effects on radial-arm maze learning and long-term nicotine consumption in mice. Behav. Brain Res. 2009, 196:207-213.
158. Levin E.D., Rose J.E., Behm F., Caskey N.H. The effects of smoking-related sensory cues on psychological stress. Pharmacol. Biochem. Behav. 1991, 39:265-268.
159. Levin E.D., Simon B.B., Conners C.K. Nicotine effects and attention deficit disorder. Nicotine in Psychiatry: Psychopathology and Emerging Therapeutics 2000, 203-214. Wiley, New York. P. Newhouse, M. Iasecki (Eds.).
160. Levin E.D., Wilson W., Rose J.E., McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 1996, 15:429-436.
161. Litman R.E., Su T.P., Potter W.Z., Hong W.W., Pickar D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia - comparison with the atypical neuroleptic, clozapine. Br. J. Psychiatry 1996, 168:571-579.
162. Loughead J., Ray R., Wileyto E.P., Ruparel K., Sanborn P., Siegel S., Gur R.C., Lerman C. Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Biol. Psychiatry 2010, 67:715-721.
163. Malin D.H., Lake J.R., Smith T.D., Khambati H.N., Meyers-Paal R.L., Montellano A.L., Jennings R.E., Erwin D.S., Presley S.E., Perales B.A. Bupropion attenuates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl) 2006, 184:494-503.
164. Manhaes A.C., Guthierrez M.C., Filgueiras C.C., Abreu-Villaca Y. Anxiety-like behavior during nicotine withdrawal predict subsequent nicotine consumption in adolescent C57BL/6 mice. Behav. Brain Res. 2008, 193:216-224.
165. Margolese H.C., Malchy L., Negrete J.C., Tempier R., Gill K. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr. Res. 2004, 67:157-166.
166. Markou A., Harrison A.A., Chevrette J., Hoyer D. Paroxetine combined with a 5-HT1A receptor antagonist reversed reward deficits observed during amphetamine withdrawal in rats. Psychopharmacology (Berl) 2005, 178:133-142.
167. Markou A., Kosten T.R., Koob G.F. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 1998, 18:135-174.
168. Marks M.J., Collins A.C. Tolerance, cross-tolerance, and receptors after chronic nicotine or oxotremorine. Pharmacol. Biochem. Behav. 1985, 22:283-291.
169. Marks M.J., Romm E., Gaffney D.K., Collins A.C. Nicotine-induced tolerance and receptor changes in four mouse strains. J. Pharmacol. Exp. Ther. 1986, 237:809-819.
170. 125I]-epibatidine binding sites in C57BL/6 mouse brain are differentially affected by chronic nicotine treatment. Neuropharmacology 2004, 46:1141-1157.
171. Marks M.J., Stitzel J.A., Collins A.C. Dose-response analysis of nicotine tolerance and receptor changes in two inbred mouse strains. J. Pharmacol. Exp. Ther. 1986, 239:358-364.
172. Martellotta M.C., Kuzmin A., Zvartau E., Cossu G., Gessa G.L., Fratta W. Isradipine inhibits nicotine intravenous self-administration in drug-naive mice. Pharmacol. Biochem. Behav. 1995, 52:271-274.
173. McCallum S.E., Collins A.C., Paylor R., Marks M.J. Deletion of the beta 2 nicotinic acetylcholine receptor subunit alters development of tolerance to nicotine and eliminates receptor upregulation. Psychopharmacology (Berl) 2006, 184:314-327.
174. McClernon F.J., Kollins S.H. ADHD and smoking: from genes to brain to behavior. Ann. N. Y. Acad. Sci. 2008, 1141:131-147.
175. McEchron M.D., Bouwmeester H., Tseng W., Weiss C., Disterhoft J.F. Hippocampectomy disrupts auditory trace fear conditioning and contextual fear conditioning in the rat. Hippocampus 1998, 8:638-646.
176. Meguro K., Yamaguchi S., Arai H., Nakagawa T., Doi C., Yamada M., Ikarashi Y., Maruyama Y., Sasaki H. Nicotine improves cognitive disturbance in senescence-accelerated mice. Pharmacol. Biochem. Behav. 1994, 49:769-772.
177. Mexal S., Jenkins P.M., Lautner M.A., Iacob E., Crouch E.L., Stitzel J.A. Alpha7 nicotinic receptor gene promoter polymorphisms in inbred mice affect expression in a cell type-specific fashion. J. Biol. Chem. 2007, 282:13220-13227.
178. Miller E.N., Fujioka T.A., Chapman L.J., Chapman J.P. Hemispheric asymmetries of function in patients with major affective disorders. J. Psychiatr. Res. 1995, 29:173-183.
179. Mizoguchi H., Ibi D., Takase F., Nagai T., Kamei H., Toth E., Sato J., Takuma K., Yamada K. Nicotine ameliorates impairment of working memory in methamphetamine-treated rats. Behav. Brain Res. 2011, 220:159-163.
180. Moragrega I., Carrasco M.C., Vicens P., Redolat R. Spatial learning in male mice with different levels of aggressiveness: effects of housing conditions and nicotine administration. Behav. Brain Res. 2003, 147:1-8.
181. Myers C.S., Taylor R.C., Moolchan E.T., Heishman S.J. Dose-related enhancement of mood and cognition in smokers administered nicotine nasal spray. Neuropsychopharmacology 2008, 33:588-598.
182. Navratilova E., Xie J.Y., King T., Porreca F. Evaluation of reward from pain relief. Ann. N. Y. Acad. Sci. 2013, 1282:1-11.
183. Naylor C., Quarta D., Fernandes C., Stolerman I.P. Tolerance to nicotine in mice lacking alpha7 nicotinic receptors. Psychopharmacology (Berl) 2005, 180:558-563.
184. Nides M., Oncken C., Gonzales D., Rennard S., Watsky E.J., Anziano R., Reeves K.R. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch. Intern. Med. 2006, 166:1561-1568.
185. Obinu M.C., Reibaud M., Miquet J.M., Pasquet M., Rooney T. Brain-selective stimulation of nicotinic receptors by TC-1734 enhances ACh transmission from frontoparietal cortex and memory in rodents. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:913-918.
186. Oliverio A. Effects of nicotine and strychnine on transfer of avoidance learning in the mouse. Life Sci. 1968, 7:1163-1167.
187. Oncken C., Gonzales D., Nides M., Rennard S., Watsky E., Billing C.B., Anziano R., Reeves K. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch. Intern. Med. 2006, 166:1571-1577.
188. Paterson N.E., Balfour D.J., Markou A. Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. Eur. J. Neurosci. 2007, 25:3099-3108.
189. Paterson N.E., Markou A. Animal models and treatments for addiction and depression co-morbidity. Neurotox. Res. 2007, 11:1-32.
190. Paterson N.E., Semenova S., Gasparini F., Markou A. The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl) 2003, 167:257-264.
191. Patterson F., Jepson C., Loughead J., Perkins K., Strasser A.A., Siegel S., Frey J., Gur R., Lerman C. Working memory deficits predict short-term smoking resumption following brief abstinence. Drug Alcohol Depend. 2010, 106:61-64.
192. Pattij T., Janssen M.C., Loos M., Smit A.B., Schoffelmeer A.N., van Gaalen M.M. Strain specificity and cholinergic modulation of visuospatial attention in three inbred mouse strains. Genes Brain Behav. 2007, 6:579-587.
193. Paylor R., Nguyen M., Crawley J.N., Patrick J., Beaudet A., Orr-Urtreger A. Alpha7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: a behavioral characterization of Acra7-deficient mice. Learn. Mem. 1998, 5:302-316.
194. Pergadia M.L., Der-Avakian A., D'Souza M.S., Madden P.A.F., Heath A.C., Shiffman S., Markou A., Pizzagalli D.A. Withdrawal of nicotine blunts reward responsiveness in humans and rats. JAMA Psychiatry 2014, 71:1238-1245.
195. Petersen D.R., Norris K.J., Thompson J.A. A comparative study of the disposition of nicotine and its metabolites in three inbred strains of mice. Drug Metab. Dispos. 1984, 12:725-731.
196. Pettiford J., Kozink R.V., Lutz A.M., Kollins S.H., Rose J.E., McClernon F.J. Increases in impulsivity following smoking abstinence are related to baseline nicotine intake and boredom susceptibility. Addict. Behav. 2007, 32:2351-2357.
197. Picciotto M.R., Zoli M., Lena C., Bessis A., Lallemand Y., Le Novere N., Vincent P., Pich E.M., Brulet P., Changeux J.P. Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 1995, 374:65-67.
198. Pickens C.L., Airavaara M., Theberge F., Fanous S., Hope B.T., Shaham Y. Neurobiology of the incubation of drug craving. Trends Neurosci. 2011, 34:411-420.
199. Pickens C.L., Navarre B.M., Nair S.G. Incubation of conditioned fear in the conditioned suppression model in rats: role of food-restriction conditions, length of conditioned stimulus, and generality to conditioned freezing. Neuroscience 2010, 169:1501-1510.
200. Pizzagalli D.A., Jahn A.L., O'Shea J.P. Toward an objective characterization of an anhedonic phenotype: a signal detection approach. Biol. Psychiatry 2005, 57:319-327.
201. Pomerleau O.F., Downey K.K., Stelson F.W., Pomerleau C.S. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J. Subst. Abuse 1995, 7:373-378.
202. Poole R.L., Connor D.A., Gould T.J. Donepezil reverses nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6J mice. Behav. Neurosci. 2014, 128:588-593.
203. Portugal G.S., Gould T.J. Bupropion dose-dependently reverses nicotine withdrawal deficits in contextual fear conditioning. Pharmacol. Biochem. Behav. 2007, 88:179-187.
204. Portugal G.S., Gould T.J. Nicotine withdrawal disrupts new contextual learning. Pharmacol. Biochem. Behav. 2009, 92:117-123.
205. Portugal G.S., Kenney J.W., Gould T.J. Beta2 subunit containing acetylcholine receptors mediate nicotine withdrawal deficits in the acquisition of contextual fear conditioning. Neurobiol. Learn. Mem. 2008, 89:106-113.
206. Prochazka A.V., Weaver M.J., Keller R.T., Fryer G.E., Licari P.A., Lofaso D. A randomized trial of nortriptyline for smoking cessation. Arch. Intern. Med. 1998, 158:2035-2039.
207. Ralph R.J., Paulus M.P., Fumagalli F., Caron M.G., Geyer M.A. Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. J. Neurosci. 2001, 21:305-313.
208. Rasmussen T., Swedberg M.D. Reinforcing effects of nicotinic compounds: intravenous self-administration in drug-naive mice. Pharmacol. Biochem. Behav. 1998, 60:567-573.
209. Raybuck J.D., Gould T.J. Extracellular signal-regulated kinase 1/2 involvement in the enhancement of contextual fear conditioning by nicotine. Behav. Neurosci. 2007, 121:1119-1124.
210. Raybuck J.D., Gould T.J. Nicotine withdrawal-induced deficits in trace fear conditioning in C57BL/6 mice - a role for high-affinity beta2 subunit-containing nicotinic acetylcholine receptors. Eur. J. Neurosci. 2009, 29:377-387.
211. Raybuck J.D., Gould T.J. The role of nicotinic acetylcholine receptors in the medial prefrontal cortex and hippocampus in trace fear conditioning. Neurobiol. Learn. Mem. 2010, 94:353-363.
212. Raybuck J.D., Portugal G.S., Lerman C., Gould T.J. Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice. Behav. Neurosci. 2008, 122:1166-1171.
213. Ren K., Thinschmidt J., Liu J., Ai L., Papke R.L., King M.A., Hughes J.A., Meyer E.M. alpha7 Nicotinic receptor gene delivery into mouse hippocampal neurons leads to functional receptor expression, improved spatial memory-related performance, and tau hyperphosphorylation. Neuroscience 2007, 145:314-322.
214. Rezayof A., Shirazi-Zand Z., Zarrindast M.R., Nayer-Nouri T. Nicotine improves ethanol-induced memory impairment: the role of dorsal hippocampal NMDA receptors. Life Sci. 2010, 86:260-266.
215. Roberts M.E., Fuemmeler B.F., McClernon F.J., Beckham J.C. Association between trauma exposure and smoking in a population-based sample of young adults. J. Adolesc. Health 2008, 42:266-274.
216. Rollema H., Hajos M., Seymour P.A., Kozak R., Majchrzak M.J., Guanowsky V., Horner W.E., Chapin D.S., Hoffmann W.E., Johnson D.E., McLean S., Freeman J., Williams K.E. Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem. Pharmacol. 2009, 78:813-824.
217. Rueter L.E., Anderson D.J., Briggs C.A., Donnelly-Roberts D.L., Gintant G.A., Gopalakrishnan M., Lin N.H., Osinski M.A., Reinhart G.A., Buckley M.J., Martin R.L., McDermott J.S., Preusser L.C., Seifert T.R., Su Z., Cox B.F., Decker M.W., Sullivan J.P. ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev. 2004, 10:167-182.
218. Rushforth S.L., Allison C., Wonnacott S., Shoaib M. Subtype-selective nicotinic agonists enhance olfactory working memory in normal rats: a novel use of the odour span task. Neurosci. Lett. 2010, 471:114-118.
219. Rushforth S.L., Steckler T., Shoaib M. Nicotine improves working memory span capacity in rats following sub-chronic ketamine exposure. Neuropsychopharmacology 2011, 36:2774-2781.
220. Russell M.A.H., Feyerabend C., Cole P.V. Plasma nicotine levels after cigarette-smoking and chewing nicotine gum. Br. Med. J. 1976, 1:1043-1046.
221. Sacco K.A., Termine A., Seyal A., Dudas M.M., Vessicchio J.C., Krishnan-Sarin S., Jatlow P.I., Wexler B.E., George T.P. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch. Gen. Psychiatry 2005, 62:649-659.
222. Salas R., De Biasi M. Opposing actions of chronic stress and chronic nicotine on striatal function in mice. Neurosci. Lett. 2008, 440:32-34.
223. Salas R., Main A., Gangitano D., De Biasi M. Decreased withdrawal symptoms but normal tolerance to nicotine in mice null for the alpha7 nicotinic acetylcholine receptor subunit. Neuropharmacology 2007, 53:863-869.
224. Salas R., Pieri F., Fung B., Dani J.A., De Biasi M. Altered anxiety-related responses in mutant mice lacking the beta4 subunit of the nicotinic receptor. J. Neurosci. 2003, 23:6255-6263.
225. Scott D., Hiroi N. Emergence of dormant conditioned incentive approach by conditioned withdrawal in nicotine addiction. Biol. Psychiatry 2010, 68:726-732.
226. Scott D., Hiroi N. Deconstructing craving: dissociable cortical control of cue reactivity in nicotine addiction. Biol. Psychiatry 2011, 69:1052-1059.
227. Semenova S., Bespalov A., Markou A. Decreased prepulse inhibition during nicotine withdrawal in DBA/2J mice is reversed by nicotine self-administration. Eur. J. Pharmacol. 2003, 472:99-110.
228. Semenova S., Markou A. Clozapine treatment attenuated somatic and affective signs of nicotine and amphetamine withdrawal in subsets of rats exhibiting hyposensitivity to the initial effects of clozapine. Biol. Psychiatry 2003, 54:1249-1264.
229. Semenova S., Markou A. The alpha 2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats. Eur. Neuropsychopharm. 2010, 20:731-746.
230. Semenova S., Stolerman I.P., Markou A. Chronic nicotine administration improves attention while nicotine withdrawal induces performance deficits in the 5-choice serial reaction time task in rats. Pharmacol. Biochem. Behav. 2007, 87:360-368.
231. Shiffman S., Johnston J.A., Khayrallah M., Elash C.A., Gwaltney C.J., Paty J.A., Gnys M., Evoniuk G., DeVeaugh-Geiss J. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl) 2000, 148:33-40.
232. Shoaib M., Bizarro L. Deficits in a sustained attention task following nicotine withdrawal in rats. Psychopharmacology (Berl) 2005, 178:211-222.
233. Shoaib M., Sidhpura N., Shafait S. Investigating the actions of bupropion on dependence-related effects of nicotine in rats. Psychopharmacology (Berl) 2003, 165:405-412.
234. Silagy C., Lancaster T., Stead L., Mant D., Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 2004, CD000146.
235. Smith M.J., Barch D.M., Wolf T.J., Mamah D., Csernansky J.G. Elevated rates of substance use disorders in non-psychotic siblings of individuals with schizophrenia. Schizophr. Res. 2008, 106:294-299.
236. Snyder F.R., Henningfield J.E. Effects of nicotine administration following 12h of tobacco deprivation: assessment on computerized performance tasks. Psychopharmacology (Berl) 1989, 97:17-22.
237. Sorensen H.J., Mortensen E.L., Reinisch J.M., Mednick S.A. A prospective study of smoking in young women and risk of later psychiatric hospitalization. Nord. J. Psychiatry 2011, 65:3-8.
238. Stevens K.E., Freedman R., Collins A.C., Hall M., Leonard S., Marks M.J., Rose G.M. Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacology 1996, 15:152-162.
239. Stevens K.E., Kem W.R., Mahnir V.M., Freedman R. Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology (Berl) 1998, 136:320-327.
240. Stoker A.K., Olivier B., Markou A. Role of alpha7- and beta4-containing nicotinic acetylcholine receptors in the affective and somatic aspects of nicotine withdrawal: studies in knockout mice. Behav. Genet. 2012, 42:423-436.
241. Stoker A.K., Semenova S., Markou A. Affective and somatic aspects of spontaneous and precipitated nicotine withdrawal in C57BL/6J and BALB/cByJ mice. Neuropharmacology 2008, 54:1223-1232.
242. Stolerman I.P., Mirza N.R., Hahn B., Shoaib M. Nicotine in an animal model of attention. Eur. J. Pharmacol. 2000, 393:147-154.
243. Sweet L.H., Mulligan R.C., Finnerty C.E., Jerskey B.A., David S.P., Cohen R.A., Niaura R.S. Effects of nicotine withdrawal on verbal working memory and associated brain response. Psychiatry Res. 2010, 183:69-74.
244. Tang J., Dani J.A. Dopamine enables in vivo synaptic plasticity associated with the addictive drug nicotine. Neuron 2009, 63:673-682.
245. Thorndike F.P., Wernicke R., Pearlman M.Y., Haaga D.A.F. Nicotine dependence, PTSD symptoms, and depression proneness among male and female smokers. Addict. Behav. 2006, 31:223-231.
246. Tidey J.W., Rohsenow D.J., Kaplan G.B., Swift R.M. Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls. Drug Alcohol Depend. 2005, 80:259-265.
247. Uchiumi O., Kasahara Y., Fukui A., Hall F.S., Uhl G.R., Sora I. Serotonergic involvement in the amelioration of behavioral abnormalities in dopamine transporter knockout mice by nicotine. Neuropharmacology 2013, 64:348-356.
248. Uhl G.R., Hall F.S., Sora I. Cocaine, reward, movement and monoamine transporters. Mol. Psychiatry 2002, 7:21-26.
249. Valzelli L., Baiguerra G., Giraud O. Difference in learning and retention by Albino Swiss mice. Part III. Effect of some brain stimulants. Methods Find. Exp. Clin. Pharmacol. 1986, 8:337-341.
250. Velicer W.F., Prochaska J.O., Rossi J.S., Snow M.G. Assessing outcome in smoking cessation studies. Psychol. Bull. 1992, 111:23-41.
251. Vinkers C.H., de Jong N.M., Kalkman C.J., Westphal K.G., van Oorschot R., Olivier B., Korte S.M., Groenink L. Stress-induced hyperthermia is reduced by rapid-acting anxiolytic drugs independent of injection stress in rats. Pharmacol. Biochem. Behav. 2009, 93:413-418.
252. Wallace T.L., Bertrand D. Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia. Expert Opin. Ther. Targets 2013, 17:139-155.
253. Wallace T.L., Porter R.H.P. Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease. Biochem. Pharmacol. 2011, 82:891-903.
254. Warner C., Shoaib M. How does bupropion work as a smoking cessation aid?. Addict. Biol. 2005, 10:219-231.
255. Watkins S.S., Koob G.F., Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob. Res. 2000, 2:19-37.
256. Watkins S.S., Stinus L., Koob G.F., Markou A. Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. J. Pharmacol. Exp. Ther. 2000, 292:1053-1064.
257. Waxmonsky J.A., Thomas M.R., Miklowitz D.J., Allen M.H., Wisniewski S.R., Zhang H.W., Ostacher M.J., Fossey M.D. Prevalence and correlates of tobacco use in bipolar disorder: data from the first 2000 participants in the Systematic Treatment Enhancement Program. Gen. Hosp. Psychiatry 2005, 27:321-328.
258. Wehner J.M., Keller J.J., Keller A.B., Picciotto M.R., Paylor R., Booker T.K., Beaudet A., Heinemann S.F., Balogh S.A. Role of neuronal nicotinic receptors in the effects of nicotine and ethanol on contextual fear conditioning. Neuroscience 2004, 129:11-24.
259. Weinberger A.H., Maciejewski P.K., Mckee S.A., Reutenauer E.L., Mazure C.M. Gender differences in associations between lifetime alcohol, depression, panic disorder, and posttraumatic stress disorder and tobacco withdrawal. Am. J. Addict. 2009, 18:140-147.
260. Weiss S., Nosten-Bertrand M., McIntosh J.M., Giros B., Martres M.P. Nicotine improves cognitive deficits of dopamine transporter knockout mice without long-term tolerance. Neuropsychopharmacology 2007, 32:2465-2478.
261. Weiss S., Tzavara E.T., Davis R.J., Nomikos G.G., Michael McIntosh J., Giros B., Martres M.P. Functional alterations of nicotinic neurotransmission in dopamine transporter knock-out mice. Neuropharmacology 2007, 52:1496-1508.
262. Wilkinson D.S., Gould T.J. The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice. Behav. Brain Res. 2011, 223:53-57.
263. Wing V.C., Shoaib M. Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal. Psychopharmacology (Berl) 2007, 195:303-313.
264. Yamashita M., Fukushima S., Shen H.W., Hall F.S., Uhl G.R., Numachi Y., Kobayashi H., Sora I. Norepinephrine transporter blockade can normalize the prepulse inhibition deficits found in dopamine transporter knockout mice. Neuropsychopharmacology 2006, 31:2132-2139.
265. Yip S.W., Sacco K.A., George T.P., Potenza M.N. Risk/reward decision-making in schizophrenia: a preliminary examination of the influence of tobacco smoking and relationship to Wisconsin Card Sorting Task performance. Schizophr. Res. 2009, 110:156-164.
266. Young J.W., Finlayson K., Spratt C., Marston H.M., Crawford N., Kelly J.S., Sharkey J. Nicotine improves sustained attention in mice: evidence for involvement of the alpha7 nicotinic acetylcholine receptor. Neuropsychopharmacology 2004, 29:891-900.
267. Young J.W., Geyer M.A. Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem. Pharmacol. 2013, 86:1122-1132.
268. Young J.W., Light G.A., Marston H.M., Sharp R., Geyer M.A. The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. PLoS ONE 2009, 4.
269. Young J.W., Meves J.M., Geyer M.A. Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test. Behav. Brain Res. 2013, 240:119-133.
270. Young J.W., Meves J.M., Tarantino I.S., Caldwell S., Geyer M.A. Delayed procedural learning in alpha 7-nicotinic acetylcholine receptor knockout mice. Genes Brain Behav. 2011, 10:720-733.
271. Young J.W., van Enkhuizen J., Markou A., Eyler L.T., Geyer M.A. Withdrawal from Chronic Nicotine Impairs Attention in Mice and Humans as Measured by the 5-Choice Continuous Performance Test: A Model for Identifying Treatments 2012, Society for Neuroscience, 696.604.
272. Zarrindast M.R., Sadegh M., Shafaghi B. Effects of nicotine on memory retrieval in mice. Eur. J. Pharmacol. 1996, 295:1-6.
273. Zhang T.A., Tang J., Pidoplichko V.I., Dani J.A. Addictive nicotine alters local circuit inhibition during the induction of in vivo hippocampal synaptic potentiation. J. Neurosci. 2010, 30:6443-6453.